143 related articles for article (PubMed ID: 30348812)
1. Extracorporeal Removal of Light Chains: New Data and Continued Controversies.
Finkel KW; Gallieni M
Clin J Am Soc Nephrol; 2018 Nov; 13(11):1753-1754. PubMed ID: 30348812
[No Abstract] [Full Text] [Related]
2. [Update in multiple myeloma: international criteria for treatment response and renal complications].
Decaux O; Karras A
Rev Med Interne; 2009 Dec; 30(12):1080-3. PubMed ID: 19833418
[No Abstract] [Full Text] [Related]
3. Extended high cutoff on-line hemodiafiltration is superior to extended high cutoff hemodialysis in removal of free light chain immunoglobulin of myeloma cast nephropathy.
Susantitaphong P; Tiranathanagul K; Eiam-Ong S
Artif Organs; 2012 Sep; 36(9):845-6. PubMed ID: 22497276
[No Abstract] [Full Text] [Related]
4. Paraprotein-Related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy.
Finkel KW; Cohen EP; Shirali A; Abudayyeh A;
Clin J Am Soc Nephrol; 2016 Dec; 11(12):2273-2279. PubMed ID: 27526708
[TBL] [Abstract][Full Text] [Related]
5. Reversible acute kidney injury (AKI) by active removal of serum light chains in an HIV positive patient with myeloma kidney.
Sowole L; Burns A; Kaur B; Davenport A
Clin Nephrol; 2011 Nov; 76(5):417-20. PubMed ID: 22000564
[TBL] [Abstract][Full Text] [Related]
6. The treatment of paraprotein-related kidney disease.
Hutchison CA; Xiong F; Mollee P
Curr Opin Nephrol Hypertens; 2017 Nov; 26(6):477-483. PubMed ID: 28885307
[TBL] [Abstract][Full Text] [Related]
7. A novel option for reducing free light chains in myeloma kidney: supra-hemodiafiltration with endogenous reinfusion (HFR).
Pasquali S; Iannuzzella F; Corradini M; Mattei S; Bovino A; Stefani A; Palladino G; Caiazzo M
J Nephrol; 2015 Apr; 28(2):251-4. PubMed ID: 25149172
[TBL] [Abstract][Full Text] [Related]
8. [Improved prognosis in light chain nephropathy due to multiple myeloma].
Juul JS; Larsen T; Marcussen N; Pedersen EB
Ugeskr Laeger; 2012 Apr; 174(17):1159-60. PubMed ID: 22533933
[TBL] [Abstract][Full Text] [Related]
9. Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology.
Fabbrini P; Finkel K; Gallieni M; Capasso G; Cavo M; Santoro A; Pasquali S
J Nephrol; 2016 Dec; 29(6):735-746. PubMed ID: 27757797
[TBL] [Abstract][Full Text] [Related]
10. The importance of screening for serum free light chains in suspected cases of multiple myeloma and their impact on the kidney.
Talbot B; Wright D; Basnayake K
BMJ Case Rep; 2014 Oct; 2014():. PubMed ID: 25326567
[TBL] [Abstract][Full Text] [Related]
11. Extracorporeal treatment of cast nephropathy.
Gakhar B; Kobrin S; Berns JS
Semin Dial; 2011; 24(1):9-11. PubMed ID: 21324000
[TBL] [Abstract][Full Text] [Related]
12. The rationale and evidence base for the direct removal of serum-free light chains in the management of myeloma kidney.
Cockwell P; Cook M
Adv Chronic Kidney Dis; 2012 Sep; 19(5):324-32. PubMed ID: 22920643
[TBL] [Abstract][Full Text] [Related]
13. Renal improvement in myeloma with plasma exchange.
Hutchison C; Bridoux F; Fermand JP
N Engl J Med; 2011 Sep; 365(11):1061; author reply 1062. PubMed ID: 21916654
[No Abstract] [Full Text] [Related]
14. Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.
Dimopoulos MA; Roussou M; Gavriatopoulou M; Psimenou E; Eleutherakis-Papaiakovou E; Migkou M; Matsouka C; Mparmparousi D; Gika D; Kafantari E; Ziogas D; Fotiou D; Panagiotidis I; Terpos E; Kastritis E
Am J Hematol; 2016 May; 91(5):499-502. PubMed ID: 26890495
[TBL] [Abstract][Full Text] [Related]
15. The use of different dialysis membranes in therapy of patients with multiple myeloma.
Szymczak M; Zielińska D; Musiała A
Polim Med; 2019; 49(2):67-70. PubMed ID: 32544311
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of IHD with Adsorptive PMMA Membrane in Myeloma Cast Nephropathy: A Cohort Study.
Sens F; Chaintreuil D; Jolivot A; Guebre-Egziabher F; Robinson P; Karlin L; Bridoux F; Juillard L
Am J Nephrol; 2017; 46(5):355-363. PubMed ID: 29017155
[TBL] [Abstract][Full Text] [Related]
17. Renal improvement in myeloma with bortezomib plus plasma exchange.
Burnette BL; Leung N; Rajkumar SV
N Engl J Med; 2011 Jun; 364(24):2365-6. PubMed ID: 21675906
[No Abstract] [Full Text] [Related]
18. Reduction of serum free light chains predict renal recovery.
Hutchison CA
Ann Hematol; 2010 Jun; 89(6):627-8. PubMed ID: 19784650
[No Abstract] [Full Text] [Related]
19. Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.
Zannetti BA; Zamagni E; Santostefano M; De Sanctis LB; Tacchetti P; Mancini E; Pantani L; Brioli A; Rizzo R; Mancuso K; Rocchi S; Pezzi A; Borsi E; Terragna C; Marzocchi G; Santoro A; Cavo M
Am J Hematol; 2015 Jul; 90(7):647-52. PubMed ID: 25858483
[TBL] [Abstract][Full Text] [Related]
20. The impact of the introduction of bortezomib on dialysis independence in multiple myeloma patients with renal impairment: a nationwide Dutch population-based study.
Oortgiesen BE; Azad R; Hemmelder MH; Kibbelaar RE; Veeger NJGM; de Vries JC; van Roon EN; Hoogendoorn M
Haematologica; 2018 Jul; 103(7):e311-e314. PubMed ID: 29545339
[No Abstract] [Full Text] [Related]
[Next] [New Search]
